Integrated Glycoproteomics Identifies Dynamic IgA1 N-Glycosylation and FUT8 as a Functional Mediator in Multiple Myeloma [0.03%]
整合糖蛋白组学鉴定出IgA1岩藻糖基转移酶FUT8在动态多发性骨髓瘤中的功能中介作用
Xu Si,Rui Zhao,Yichuan Song et al.
Xu Si et al.
Aberrant protein glycosylation is pivotal in cancer progression. However, the IgA glycosylation landscape in multiple myeloma (MM) and its regulatory mechanisms remain uncharacterized. We conducted a comprehensive glycoproteomic analysis of...
Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight [0.03%]
难治性病因特发多中心Castleman病患者单次输注CD19 CAR-T细胞后的持续完全缓解：一项带有机制见解的病例报告
Yajing Zhang,Fangfang Cheng,Biping Deng et al.
Yajing Zhang et al.
Idiopathic multicentric Castleman disease (iMCD) is rare and life-threatening; although siltuximab is standard first-line therapy, a substantial proportion of patients are refractory or experience relapse. We report a 31-year-old woman with...
Case Reports
Hematological oncology. 2026 Jul;44(4):e70214. DOI:10.1002/hon.70214 2026
Efficacy and Safety of Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic Review and Meta-Analysis [0.03%]
新型药物一线疗法治疗≥60岁经典型霍奇金淋巴瘤老年患者的疗效和安全性：系统评价和Meta分析
Rudra Narayan Swain,Charanpreet Singh,Aditya Jandial et al.
Rudra Narayan Swain et al.
Older patients with classical Hodgkin lymphoma (cHL) have poorer outcomes than younger patients, largely due to comorbidities, reduced chemotherapy tolerance, and limited representation in clinical trials. Brentuximab Vedotin (BV) and PD-1 ...
Meta-Analysis
Hematological oncology. 2026 Jul;44(4):e70215. DOI:10.1002/hon.70215 2026
Extracorporeal Cytokine Hemadsorption for the Treatment of Severe Steroid Refractory Cytokine Release Syndrome Secondary to T-Cell Immunotherapy for B-Cell Malignancies: A Case Series [0.03%]
体外细胞因子吸附治疗T细胞免疫治疗B细胞恶性肿瘤所致重度类固醇耐药性细胞因子释放综合征的案例系列分析
Gianluca Cavallaro,Silvia Ferrari,Anna Pollastri et al.
Gianluca Cavallaro et al.
Glofitamab Induces Complete Responses in Relapsed and Refractory Primary Central Nervous System Lymphoma [0.03%]
Glofitamab治疗复发和难治性原发中枢神经系统淋巴瘤可诱导完全缓解
Coen J Lap,James Di Palma-Grisi,Andrew Ip et al.
Coen J Lap et al.
Although most patients with primary central nervous system lymphoma (PCNSL) respond to treatment with high-dose methotrexate-containing regimens, over 50% relapse and 15% is refractory to treatment. The prognosis of these patients is poor, ...
Case Reports
Hematological oncology. 2026 Jul;44(4):e70211. DOI:10.1002/hon.70211 2026
Impact of U2AF1 Pathogenic Variants on Prognosis of Myelodysplastic Neoplasms With RUNX1 Mutation [0.03%]
U2AF1致病突变对RUNX1突变骨髓增生异常肿瘤预后的影响
Linlin Liu,Bing Li,Tiejun Qin et al.
Linlin Liu et al.
RUNX1 is one of the most commonly mutated genes in myelodysplastic neoplasms (MDS) and essential for hematopoiesis. However, clinical phenotype features of RUNX1 mutated patients and the interaction between RUNX1 and other genes mutations r...
CAR T Cell Therapy in Solid Tumors: Lessons From Early-Phase Clinical Trials and Biological Barriers to Efficacy [0.03%]
嵌合抗原受体T细胞治疗实体瘤：早期临床试验的经验与生物屏障限制了疗效
Kasie Liu,Vincent Truong Pham,Shaozi Fu et al.
Kasie Liu et al.
Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of select hematologic malignancies, where disease accessibility, well-defined lineage antigens, and clinically manageable target cell depletion have enabled more d...
Integrative Transcriptomic and Functional Analysis of PKMYT1 Reveals a Potential Therapeutic Target in Chronic Lymphocytic Leukemia [0.03%]
PKMYT1的整合转录组和功能分析揭示其可能是慢性淋巴细胞性白血病的治疗靶点
Elizabete Cristina Iseke Bispo,Cláudia de Souza Lima Pontes,Jennifer Martins do Nascimento et al.
Elizabete Cristina Iseke Bispo et al.
Chronic lymphocytic leukemia (CLL) is a clinically and molecularly heterogeneous disease. PKMYT1, a G2/M cell cycle kinase, has been implicated in tumor progression in several cancers, but its role in CLL remains unclear. We evaluated PKMYT...
Mutational Landscape and Clinical Outcomes in AML With Sole Trisomy 8 [0.03%]
单独8号染色体三倍体现在白血病中的突变图谱及临床预后
Ehsan Bahrami Hezaveh,Mark Anthony Turingan,Qianghua Zhou et al.
Ehsan Bahrami Hezaveh et al.
In acute myeloid leukemia (AML), gaining chromosome 8 as the sole abnormality (sole +8) is rare. The prognostic impact and mutation profile of sole +8 AML remain unclear. We retrospectively analyzed a cohort of 75 patients with sole +8 AMLs...
Bendamustine/Rituximab Induction Followed by Venetoclax/Rituximab Consolidation in Frontline Treatment of Chronic Lymphocytic Leukemia: A Phase 2 Multi-Center Study [0.03%]
苯达莫司汀/利妥昔单抗联合诱导治疗后使用维奈克拉/利妥昔单抗进行consolidation治疗一线治疗慢性淋巴细胞白血病的多中心II期临床研究
Andrew H Lipsky,Brian T Hill,Allison Winter et al.
Andrew H Lipsky et al.
We hypothesized that a time-limited frontline treatment strategy with abbreviated chemoimmunotherapy followed by targeted consolidation could achieve durable disease control with manageable toxicity in CLL. We evaluated the safety and effic...
Clinical Trial
Hematological oncology. 2026 Jul;44(4):e70205. DOI:10.1002/hon.70205 2026